JP2016513970A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513970A5
JP2016513970A5 JP2016501585A JP2016501585A JP2016513970A5 JP 2016513970 A5 JP2016513970 A5 JP 2016513970A5 JP 2016501585 A JP2016501585 A JP 2016501585A JP 2016501585 A JP2016501585 A JP 2016501585A JP 2016513970 A5 JP2016513970 A5 JP 2016513970A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
dengue
virus
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501585A
Other languages
English (en)
Japanese (ja)
Other versions
JP6818548B2 (ja
JP2016513970A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/024603 external-priority patent/WO2014150939A2/en
Publication of JP2016513970A publication Critical patent/JP2016513970A/ja
Publication of JP2016513970A5 publication Critical patent/JP2016513970A5/ja
Application granted granted Critical
Publication of JP6818548B2 publication Critical patent/JP6818548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501585A 2013-03-15 2014-03-12 ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法 Active JP6818548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15
US61/800,204 2013-03-15
PCT/US2014/024603 WO2014150939A2 (en) 2013-03-15 2014-03-12 Compositions and methods for dengue virus chimeric constructs in vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019105307A Division JP7050031B2 (ja) 2013-03-15 2019-06-05 ワクチンにおけるデングウイルスキメラおよび組成物

Publications (3)

Publication Number Publication Date
JP2016513970A JP2016513970A (ja) 2016-05-19
JP2016513970A5 true JP2016513970A5 (https=) 2017-04-13
JP6818548B2 JP6818548B2 (ja) 2021-01-20

Family

ID=50678274

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501585A Active JP6818548B2 (ja) 2013-03-15 2014-03-12 ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法
JP2019105307A Active JP7050031B2 (ja) 2013-03-15 2019-06-05 ワクチンにおけるデングウイルスキメラおよび組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019105307A Active JP7050031B2 (ja) 2013-03-15 2019-06-05 ワクチンにおけるデングウイルスキメラおよび組成物

Country Status (33)

Country Link
US (6) US9783579B2 (https=)
EP (5) EP2968516B1 (https=)
JP (2) JP6818548B2 (https=)
KR (4) KR102389908B1 (https=)
CN (5) CN113637693B (https=)
AR (4) AR095598A1 (https=)
AU (2) AU2014235476B2 (https=)
CA (4) CA3177574C (https=)
CR (1) CR20150569A (https=)
DK (1) DK4129330T5 (https=)
DO (1) DOP2015000232A (https=)
EC (1) ECSP23013715A (https=)
ES (2) ES2933970T3 (https=)
FI (2) FI3539565T3 (https=)
FR (1) FR22C1064I2 (https=)
HR (1) HRP20231581T1 (https=)
HU (2) HUE061507T2 (https=)
LT (2) LT4129330T (https=)
LU (1) LUC00329I2 (https=)
MX (5) MX374519B (https=)
MY (1) MY187796A (https=)
NL (1) NL301223I2 (https=)
NO (1) NO2023026I1 (https=)
NZ (1) NZ630869A (https=)
PE (2) PE20160027A1 (https=)
PH (1) PH12015502120B1 (https=)
PL (1) PL3539565T3 (https=)
PT (1) PT3539565T (https=)
SG (3) SG10201913387XA (https=)
SI (1) SI4129330T1 (https=)
TW (4) TWI733646B (https=)
UY (1) UY35489A (https=)
WO (1) WO2014150939A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
KR102373570B1 (ko) * 2015-11-27 2022-03-10 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
EP3892737A1 (en) * 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
US20250342705A1 (en) 2022-05-04 2025-11-06 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
CN116479167A (zh) * 2022-08-30 2023-07-25 深圳大学 登革病毒的pcr检测方法
EP4605562A1 (en) * 2022-10-20 2025-08-27 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells
CN119824145A (zh) * 2025-03-03 2025-04-15 广州市疾病预防控制中心(广州市卫生检验中心、广州市食品安全风险监测与评估中心、广州医科大学公共卫生研究院) 一种对登革病毒的逆转录产物进行扩增的pcr引物、pcr试剂盒以及检测登革病毒的方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
EP1018556B1 (en) 1991-09-19 2005-11-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
DE69624815T2 (de) 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
AU9794198A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric vaccine against tick-borne encephalitis virus
IL139844A0 (en) 1998-06-04 2002-02-10 Us Gov Health & Human Serv Nucleic acid vaccines for prevention of flavivirus infection
DE29810020U1 (de) 1998-06-04 1998-09-24 Siemens AG, 80333 München Kunststoffbehälter zur Tieftemperaturlagerung von biologischen Materialien
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
ATE526411T1 (de) * 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
WO2002072036A2 (en) 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
CA2611954C (en) 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
ATE547425T1 (de) 2007-07-13 2012-03-15 Florida Gulf Coast University Optimiertes dengue-virus-eintrittshemmendes peptid (dn81)
AU2009241354B2 (en) * 2008-04-30 2014-06-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric West Nile/Dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
AU2010256845B2 (en) 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
JP2015520196A (ja) 2012-06-10 2015-07-16 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対するワクチン投与のための組成物および方法
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
AU2013295016A1 (en) 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
TW201428101A (zh) * 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型4型之建構物的組成物、方法及用途
US9878031B2 (en) * 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
JP2019511533A (ja) 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MY209364A (en) 2017-10-16 2025-07-03 Serum Institute Of India Pvt Ltd Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
EP3892737A1 (en) 2020-04-09 2021-10-13 Takeda Vaccines, Inc. Qualitative and quantitative determination of single virus haplotypes in complex samples

Similar Documents

Publication Publication Date Title
JP2016513970A5 (https=)
JP2016501015A5 (ja) デングウイルス血清型4(den−4)構築物に関する組成物、方法および使用
AR132009A2 (es) Moléculas de polinucleótido y de polipéptido, virus de dengue, composiciones, vector y célula
US8088391B2 (en) West nile virus vaccine
JP6486827B2 (ja) デングウイルス血清型4(den−4)構築物に関する核酸分子、組成物および使用
CA2650591C (en) Methods for the treatment of flavivirus infection, molecules and uses thereof
HUP0002139A2 (hu) Kiméra flavivírus-vakcinák
JP2019511533A5 (https=)
JP2008520187A5 (https=)
US9878031B2 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
CA2584228A1 (en) Vaccines against japanese encephalitis virus and west nile virus
AU2008203442B2 (en) Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
CA2622827C (en) Pharmaceutical compound capable of inducing immune protective response against dengue virus having the capsid protein of the dengue virus
CN101970467A (zh) 用作疫苗的在衣壳蛋白中包含缺失的黄病毒科突变体
AU2019203166B2 (en) Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
Maramorosch et al. The Flaviviruses: Pathogenesis and Immunity
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน